LogicFlo AI, a company building the AI agent workforce for life sciences, has announced a $2.7 million seed funding round to scale its intelligent agent platform across the pharmaceutical, biotech, and medtech industries. The round was led by Lightspeed with participation from leading healthcare and enterprise AI investors. It will fund product expansion, team growth, and deeper deployments with global life sciences organisations, including a Fortune 500 customer already under contract. 

Founded by Udith Vaidyanathan and Arun Ramakrishnan, the platform gives every life sciences expert their own team of intelligent agents – AI collaborators designed to execute tasks under human guidance.

“While the rest of the world is focused on automation instead of people, we are building automation for people,” said Udith Vaidyanathan, LogicFlo’s co-founder and CEO. “LogicFlo puts experts firmly at the centre. The goal is to let the brightest people in life sciences do what only they can do - drive medical science forward and help elevate the standard of care.”

Vaidyanathan previously steered key business units from inside Abbott’s CEO office before dropping out of Harvard Business School to build LogicFlo AI.

Arun Ramakrishnan, co-founder and CTO, previously led deep learning efforts at Intuitive Surgical, where he built high-precision AI models for the Da Vinci robotic system deployed in real-world surgeries. “Traditional automation has failed life sciences because it’s too rigid, too brittle, and too out of touch with how people work,” he explained. “Our agents are different. They’re intelligent, composable, production-ready, and they understand the nuance of scientific work.”

The platform is deployed across medical affairs, regulatory, commercial, and quality teams at global pharmaceutical and medical device companies. Deployments typically begin with 20–30 active users and scale organically as teams experience the results. Medical writing outputs that took weeks can now take minutes with up to 2000x reduction in time to first draft – and response timelines for medical information requests have collapsed from 1-2 weeks to 1-2 days.

Rohil Bagga, VP of Investments, Lightspeed, commented: “We’re thrilled to back LogicFlo AI as they revolutionise how life sciences and biotech organisations operate. Their AI agent platform empowers medical affairs and commercial teams to build agentic workflows across diverse use cases, dramatically boosting productivity. Founders Udith and Arun combine deep domain expertise with exceptional technical acumen—we’re excited to support them as they drive transformation in one of the world’s most critical industries.”

LogicFlo’s agents support functions across the entire life sciences value chai -- medical writing with literature-based content creation and full referencing; Medical communications and information response generation with SR documents, material for ad boards, congresses, journal articles, commercial content creation with compliant promotional materials and MLR workflow management; regulatory authoring for CTAs, INDs, and safety narratives; quality and compliance documentation including SOPs, deviation reports, and CAPAs.

With this new funding, LogicFlo will expand its agent libraries, deepen integrations with life-sciences native systems like Veeva and IQVIA, and grow its team to meet rising demand across the sector.

Published on June 30, 2025